Richard Driehaus

Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives

Retrieved on: 
Wednesday, April 3, 2024
Research, Finance, Clinical Trials, Professional Services, Biotechnology, Health, General Health, Science, Oncology, OrbiMed, Drug discovery, Patient, Cancer, Sachs, Blue Owl Capital, Protein, Medicine, Richard Driehaus, Therapy, Partner

Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.

Key Points: 
  • Alterome Therapeutics, Inc. , a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing.
  • The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures.
  • Concurrent with the financing, Josh Richardson, M.D., a Managing Director within Life Sciences Investing at Goldman Sachs Alternatives, and Uwe Schoenbeck, a Partner at Canaan Partners, were named to the Board of Directors.
  • “Alterome is advancing an exciting portfolio of therapies targeting validated oncogenic drivers, with clear paths to early clinical signals,” said Dr. Josh Richardson, Managing Director within Life Sciences Investing at Goldman Sachs Alternatives.

Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement

Retrieved on: 
Wednesday, February 28, 2024
Janus, Therapy, SAN, Research, Sale, Richard Driehaus, SVB Securities, Paradigm

Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.

Key Points: 
  • Crinetics anticipates the gross proceeds from the private placement to be approximately $350 million, before deducting any offering-related expenses.
  • The private placement is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.
  • Leerink Partners, Piper Sandler, Baird, Citizens JMP, H.C. Wainwright & Co., and LifeSci Capital are acting as placement agents to the Company in connection with the private placement.
  • Crinetics has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement no later than the 40th day after the pricing of the private placement.

Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement

Retrieved on: 
Thursday, March 7, 2024
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Janus, Attention, Prospectus, Medicine, Capital market, MindMed, Telephone, RBC Capital Markets, File, Cantor, Sale, Form, Richard Driehaus, State Street, SVB Securities, Security (finance)

In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.

Key Points: 
  • In addition, the Company has entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares at a price of $6.00 per common share.
  • Gross proceeds to MindMed from the underwritten offering and concurrent private placement, before deducting underwriting commissions, placement agent fees and other offering-related expenses, are expected to be approximately $175 million.
  • Leerink Partners and Cantor are acting as joint bookrunning managers for the underwritten offering and placement agents for the private placement.
  • RBC Capital Markets is acting as lead manager for the underwritten offering and placement agent for the private placement.

Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Monday, March 4, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Allergy, Investigational New Drug, PD, Research, YTE, Hereditary angioedema, Investment, Atopic dermatitis, Richard Driehaus, Safety, OX40, HAE, Therapy, Pharmacokinetics, Patient, Pharmaceutical industry

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.
  • The trial is evaluating safety and tolerability, changes in HAE attack rate, pharmacokinetics (PK), pharmacodynamics (PD), and quality-of-life assessments.
  • Pending proof-of-concept results from the ALPHA-STAR trial, Astria expects to progress directly to a pivotal Phase 3 program which is anticipated to initiate in the first quarter of 2025.
  • Cash Position: As of December 31, 2023, Astria had cash, cash equivalents and short-term investments of $246.5 million, compared to $188.8 million as of September 30, 2023.

Skye Bioscience Announces $50.25 Million Private Placement Equity Financing

Retrieved on: 
Monday, January 29, 2024
Obesity, OE, Patient, PIPE, Richard Driehaus, Leptin, Fasting, Visium Asset Management, Sale, Ocular hypertension, OTCQB, Exchange, CB1, Safety, Triglyceride, Netarsudil, Glaucoma, Waist, Cholesterol, Security (finance), Body composition, Oppenheimer Holdings, Pharmaceutical industry

Financing co-led by a leading life science investor and 5AM Ventures expected to fully fund obesity Phase 2 trial assessing nimacimab, Skye's differentiated peripheral CB1 inhibitor, in combination with a GLP-1R agonist

Key Points: 
  • Gross proceeds from the PIPE are expected to be $50.25 million, before deducting any placement agent fees and offering-related expenses.
  • The PIPE financing is expected to close on January 31, 2024, subject to the satisfaction of customary closing conditions.
  • The PIPE financing was co-led by a life sciences-focused investor and 5AM Ventures, with participation from Ally Bridge Group, Sphera Healthcare, Altium Capital, Driehaus Capital Management and other institutional investors.
  • Piper Sandler is acting as the lead placement agent and Oppenheimer & Co. is acting as a placement agent for the PIPE financing.

LOCHNER CELEBRATES FIRST GRADUATES OF DEPAUL LEADERSHIP PROGRAM

Retrieved on: 
Thursday, August 31, 2023
Richard Driehaus, Lochner v. New York, Curriculum, Business, DePaul University College of Law, DePaul University, KOA Corporation, Growth, De Paul, Management

Lochner, Inc. ( Lochner ), a leading provider of infrastructure planning and engineering services, proudly announces the graduation of participants in the DePaul University Leadership Foundations Certificate program.

Key Points: 
  • Lochner, Inc. ( Lochner ), a leading provider of infrastructure planning and engineering services, proudly announces the graduation of participants in the DePaul University Leadership Foundations Certificate program.
  • Aligning with the company's vision to establish a market leading professional services organization, Lochner joined forces with DePaul University's Driehaus College of Business to customize a best-in-class leadership program.
  • The program is designed to accelerate management skills, helping professionals effectively think about leadership and leading people.
  • Other facilitators of the program include award-winning DePaul professor Dr. Robert S. Rubin and Manifest Financial President and CEO, David Dixon.

Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines

Retrieved on: 
Tuesday, July 11, 2023
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Professional Services, Clinical Trials, Seizure, Kidney failure, Drug development, Therapy, Venture round, G protein-coupled receptor, Goldman Sachs, Arrhythmia, Hypoparathyroidism, Lead, Brain, PTH, Fatigue, Muscle weakness, Richard Driehaus, Protein, GPCR, Third Rock Ventures, Patient, Mirae Asset Financial Group, PTH1R, Parathyroid hormone, TSHR, Pharmaceutical industry

Septerna , a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the closing of a $150 million Series B financing.

Key Points: 
  • Septerna , a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the closing of a $150 million Series B financing.
  • In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, will join Septerna’s board of directors.
  • This is an exciting time for GPCR drug development, and we are eager to move our novel products toward clinical development.
  • Septerna is focused on developing a first-in-class, oral small molecule PTH1R agonist designed to treat all patients with hypoparathyroidism.

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics

Retrieved on: 
Thursday, June 22, 2023
Paragon, LLP, Therapy, Doctor of Philosophy, Investment, Diarrhea, IBD, Biotechnology, Weight loss, TL1A, Research, Abdominal pain, Sale, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease, Richard Driehaus, Acquisition, Patient, Capital, SVP, Safety, Fatigue, Corporate development, Vaccine, Pharmaceutical industry, Management, Citadel, Michael Spyres

AUSTIN, Texas and WALTHAM, Mass., June 22, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. ("Spyre"), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Concurrent with the acquisition of Spyre, Aeglea entered into a definitive agreement for the sale of Series A non-voting convertible preferred stock (the "Series A preferred stock") in a private placement to a group of institutional accredited investors led by Fairmount Funds Management LLC ("Fairmount Funds"), with participation from Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Commodore Capital, Deep Track Capital, Perceptive Advisors, RTW Investments, Cormorant Asset Management, Driehaus Capital Management, Ecor1 Capital, RA Capital Management, Surveyor Capital (a Citadel company), and Wellington Management Company LLP, as well as additional undisclosed institutional investors. The private placement is expected to result in gross proceeds to Aeglea of approximately $210 million before deducting placement agent and other offering expenses. The proceeds from the private placement are intended to be used to advance Spyre's portfolio of potentially best-in-class IBD products through multiple data milestones and are expected to fund operations into 2026.

Key Points: 
  • Spyre is the second spinout of Paragon Therapeutics.
  • Spyre was founded to transform the treatment of IBD by pursuing potentially best-in-class long-acting antibodies, rational therapeutic combinations, and precision immunology approaches.
  • "The concurrent launch of Spyre and acquisition by Aeglea will provide immediate access to the public capital markets and the opportunity to accelerate research and development efforts for our broad pipeline of biologics," said Cameron Turtle, DPhil, newly appointed Chief Operating Officer of Aeglea.
  • "Our management and our Board of Directors thoroughly explored numerous strategic alternatives and believe this acquisition of Spyre provides a phenomenal outcome for our stockholders," said Jonathan D. Alspaugh, President and Chief Financial Officer, Aeglea.

Landmarks Illinois seeks nominations for 2023 preservation awards

Retrieved on: 
Tuesday, April 4, 2023
Partnership, Richard Driehaus, Public policy, Organization, Climate change, Economic development, Knowledge, Memory, Film industry, Landmarks Preservation Council of Illinois

CHICAGO, April 4, 2023 /PRNewswire/ -- Landmarks Illinois is now accepting nominations for the 2023 Landmarks Illinois Richard H. Driehaus Foundation Preservation Awards .

Key Points: 
  • CHICAGO, April 4, 2023 /PRNewswire/ -- Landmarks Illinois is now accepting nominations for the 2023 Landmarks Illinois Richard H. Driehaus Foundation Preservation Awards .
  • The annual awards program honors outstanding preservation projects in Illinois and/or individuals, organizations and advocacy efforts that demonstrate a strong commitment to protecting the places that are important to the people and communities of Illinois.
  • A jury of preservation professionals will review the nominations and determine the winners of this year's awards.
  • Winners of the 2023 Landmarks Illinois Richard H. Driehaus Foundation Preservation Awards will be selected from the following general categories:
    Advocacy: An effective local or statewide campaign to preserve and protect a historic resource.

VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

Retrieved on: 
Tuesday, October 18, 2022
808, U.S. Securities and Exchange Commission, MMA, Sale, Telephone, SEC filing, SEC, SBS, Short bowel syndrome, Coenzyme A, Nicollet Mall, LLC, Pantetheine, Jefferies Group, Risk, Patient, Manufacturing execution system, Madison Avenue, Degenerative disease, Attention, Nasdaq, Richard Driehaus, State Street, Community of Metros, Form, Propionic acidemia, Congenital disorders of amino acid metabolism, Phrase, GLOBE, Prospectus, Jefferies, Respiration (physiology), Forward-looking statement, Life insurance, Security (finance), Citadel

BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

Key Points: 
  • BASEL, Switzerland, Oct. 18, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (VectivBio) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.
  • Before deducting the underwriting discounts and commissions and offering expenses, VectivBio received total gross proceeds of approximately $125 million.
  • Jefferies, SVB Securities and Piper Sandler acted as the joint book-running managers for the offering.
  • VectivBio is a global clinical-stage biotechnology company focused on transforming and improving the lives of patients with severe rare conditions.